Clinical trial simulation to evaluate tenofovir disoproxil fumarate/emtricitabine HIV pre-exposure prophylaxis dosing during pregnancy

ObjectiveTo evaluate upward-adjustment of tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) pre-exposure prophylaxis (PrEP) dosing during pregnancy in order to maintain target plasma concentrations associated with HIV protection.DesignPopulation pharmacokinetic (PK) modeling and clinical trial...

Full description

Bibliographic Details
Main Authors: Rachel K. Scott, Yifan Yu, Mark A. Marzinke, Jenell S. Coleman, Craig W. Hendrix, Robert Bies
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-09-01
Series:Frontiers in Reproductive Health
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/frph.2023.1224580/full
_version_ 1797672099596206080
author Rachel K. Scott
Yifan Yu
Mark A. Marzinke
Jenell S. Coleman
Craig W. Hendrix
Robert Bies
author_facet Rachel K. Scott
Yifan Yu
Mark A. Marzinke
Jenell S. Coleman
Craig W. Hendrix
Robert Bies
author_sort Rachel K. Scott
collection DOAJ
description ObjectiveTo evaluate upward-adjustment of tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) pre-exposure prophylaxis (PrEP) dosing during pregnancy in order to maintain target plasma concentrations associated with HIV protection.DesignPopulation pharmacokinetic (PK) modeling and clinical trial simulation (CTS).Material and methodsWe developed population pharmacokinetic models for TFV and FTC using data from the Partners Demonstration Project and a PK study of TDF/FTC among cisgender women by Coleman et al., and performed an in-silico simulation. Pregnancy-trimester was identified as a significant covariate on apparent clearance in the optimized final model. We simulated 1,000 pregnant individuals starting standard daily oral TDF/FTC (300 mg/200 mg) prior to pregnancy. Upon becoming pregnant, simulated patients were split into two study arms: one continuing standard-dose and the other receiving double standard-dose throughout pregnancy.ResultsStandard-dose trough TFV concentrations were significantly lower in pregnancy compared to pre-pregnancy, with 34.0%, 43.8%, and 65.1% of trough plasma concentrations below the lower bound of expected trough concentrations presumed to be the protective threshold in the 1st, 2nd, and 3rd trimesters, respectively. By comparison, in the simulated double-dose group, 10.7%, 14.4%, and 27.8% of trough concentrations fell below the estimated protective thresholds in the 1st, 2nd, and 3rd trimesters, respectively. The FTC trough plasma concentration during pregnancy was also lower than pre-pregnancy, with 45.2% of the steady-state trough concentrations below the estimated protective trough concentrations of FTC. In the pregnancy-adjusted double-dose group, 24.1% of trough plasma concentrations were lower than protective levels.ConclusionsOur simulation shows >50% of research participants on standard dosing would have 3rd trimester trough plasma TFV concentrations below levels associated with protection. This simulation provides the quantitative basis for the design of prospective TDF/FTC studies during pregnancy to evaluate the safety and appropriateness of pregnancy-adjusted dosing.
first_indexed 2024-03-11T21:25:09Z
format Article
id doaj.art-ae73290767cb4208b9156418a7bee88a
institution Directory Open Access Journal
issn 2673-3153
language English
last_indexed 2024-03-11T21:25:09Z
publishDate 2023-09-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Reproductive Health
spelling doaj.art-ae73290767cb4208b9156418a7bee88a2023-09-28T05:24:20ZengFrontiers Media S.A.Frontiers in Reproductive Health2673-31532023-09-01510.3389/frph.2023.12245801224580Clinical trial simulation to evaluate tenofovir disoproxil fumarate/emtricitabine HIV pre-exposure prophylaxis dosing during pregnancyRachel K. Scott0Yifan Yu1Mark A. Marzinke2Jenell S. Coleman3Craig W. Hendrix4Robert Bies5omen’s Health Research, MedStar Health Research Institute, Washington, DC, United StatesDepartment of Pharmaceutical Sciences, University of Buffalo, Buffalo, NY, United StatesDivision of Clinical Pharmacology, Johns Hopkins University School of Medicine, Baltimore, MD, United StatesDepartment of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, United StatesDivision of Clinical Pharmacology, Johns Hopkins University School of Medicine, Baltimore, MD, United StatesDepartment of Pharmaceutical Sciences, University of Buffalo, Buffalo, NY, United StatesObjectiveTo evaluate upward-adjustment of tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) pre-exposure prophylaxis (PrEP) dosing during pregnancy in order to maintain target plasma concentrations associated with HIV protection.DesignPopulation pharmacokinetic (PK) modeling and clinical trial simulation (CTS).Material and methodsWe developed population pharmacokinetic models for TFV and FTC using data from the Partners Demonstration Project and a PK study of TDF/FTC among cisgender women by Coleman et al., and performed an in-silico simulation. Pregnancy-trimester was identified as a significant covariate on apparent clearance in the optimized final model. We simulated 1,000 pregnant individuals starting standard daily oral TDF/FTC (300 mg/200 mg) prior to pregnancy. Upon becoming pregnant, simulated patients were split into two study arms: one continuing standard-dose and the other receiving double standard-dose throughout pregnancy.ResultsStandard-dose trough TFV concentrations were significantly lower in pregnancy compared to pre-pregnancy, with 34.0%, 43.8%, and 65.1% of trough plasma concentrations below the lower bound of expected trough concentrations presumed to be the protective threshold in the 1st, 2nd, and 3rd trimesters, respectively. By comparison, in the simulated double-dose group, 10.7%, 14.4%, and 27.8% of trough concentrations fell below the estimated protective thresholds in the 1st, 2nd, and 3rd trimesters, respectively. The FTC trough plasma concentration during pregnancy was also lower than pre-pregnancy, with 45.2% of the steady-state trough concentrations below the estimated protective trough concentrations of FTC. In the pregnancy-adjusted double-dose group, 24.1% of trough plasma concentrations were lower than protective levels.ConclusionsOur simulation shows >50% of research participants on standard dosing would have 3rd trimester trough plasma TFV concentrations below levels associated with protection. This simulation provides the quantitative basis for the design of prospective TDF/FTC studies during pregnancy to evaluate the safety and appropriateness of pregnancy-adjusted dosing.https://www.frontiersin.org/articles/10.3389/frph.2023.1224580/fullpregnancypre-exposure prophylaxisHIV infectiontenofoviremtricitabineclinical trial simulation
spellingShingle Rachel K. Scott
Yifan Yu
Mark A. Marzinke
Jenell S. Coleman
Craig W. Hendrix
Robert Bies
Clinical trial simulation to evaluate tenofovir disoproxil fumarate/emtricitabine HIV pre-exposure prophylaxis dosing during pregnancy
Frontiers in Reproductive Health
pregnancy
pre-exposure prophylaxis
HIV infection
tenofovir
emtricitabine
clinical trial simulation
title Clinical trial simulation to evaluate tenofovir disoproxil fumarate/emtricitabine HIV pre-exposure prophylaxis dosing during pregnancy
title_full Clinical trial simulation to evaluate tenofovir disoproxil fumarate/emtricitabine HIV pre-exposure prophylaxis dosing during pregnancy
title_fullStr Clinical trial simulation to evaluate tenofovir disoproxil fumarate/emtricitabine HIV pre-exposure prophylaxis dosing during pregnancy
title_full_unstemmed Clinical trial simulation to evaluate tenofovir disoproxil fumarate/emtricitabine HIV pre-exposure prophylaxis dosing during pregnancy
title_short Clinical trial simulation to evaluate tenofovir disoproxil fumarate/emtricitabine HIV pre-exposure prophylaxis dosing during pregnancy
title_sort clinical trial simulation to evaluate tenofovir disoproxil fumarate emtricitabine hiv pre exposure prophylaxis dosing during pregnancy
topic pregnancy
pre-exposure prophylaxis
HIV infection
tenofovir
emtricitabine
clinical trial simulation
url https://www.frontiersin.org/articles/10.3389/frph.2023.1224580/full
work_keys_str_mv AT rachelkscott clinicaltrialsimulationtoevaluatetenofovirdisoproxilfumarateemtricitabinehivpreexposureprophylaxisdosingduringpregnancy
AT yifanyu clinicaltrialsimulationtoevaluatetenofovirdisoproxilfumarateemtricitabinehivpreexposureprophylaxisdosingduringpregnancy
AT markamarzinke clinicaltrialsimulationtoevaluatetenofovirdisoproxilfumarateemtricitabinehivpreexposureprophylaxisdosingduringpregnancy
AT jenellscoleman clinicaltrialsimulationtoevaluatetenofovirdisoproxilfumarateemtricitabinehivpreexposureprophylaxisdosingduringpregnancy
AT craigwhendrix clinicaltrialsimulationtoevaluatetenofovirdisoproxilfumarateemtricitabinehivpreexposureprophylaxisdosingduringpregnancy
AT robertbies clinicaltrialsimulationtoevaluatetenofovirdisoproxilfumarateemtricitabinehivpreexposureprophylaxisdosingduringpregnancy